Leerink Partners analyst Geoff Porges maintained a Buy rating on Regeneron (NASDAQ:REGN) on Tuesday, setting a price target of ...

Should Regeneron wish to compete, they will have to lower their prices, thereby eating into their profit margins. Interestingly, at the recent Leerink Global Healthcare Conference, the CFO Chris ...

In a report released on March 2, David Risinger from Leerink Partners maintained a ... AnaptysBio, and Regeneron. According to TipRanks, Risinger has an average return of 10.3% and a 56.15% ...

With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...

The Cambridge, Massachusetts-based biotech had divested its cell therapy R&D programs to Regeneron for $5 million upfront in early 2024. As the Leerink team noted, the company’s remaining ...

Based on the results, the Leerink team stood by its $4.3 billion ... commercial chief at Regeneron, said during a conference call last month. The three biologics work in different ways.

Intech Investment Management LLC raised its position in 2seventy bio, Inc. (NASDAQ:TSVT – Free Report) by 41.1% during the fourth quarter, according to the company in its most recent 13F filing with ...

The acquisition could save Bristol future profit-sharing costs in Abecma, according to Leerink analyst David Risinger. Last year, 2seventy sold all its experimental cell therapies to Regeneron ...

(Reuters) -Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares up 76% in premarket trading on Tuesday. Late on Monday, ...

In a note sent to investors Tuesday, Leerink Partners analyst Daina Graybosch ... as 2seventy already divested its R&D assets to Regeneron and Novo Nordisk, and [Bristol Myers Squibb] manufactures ...